These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6374057)

  • 1. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
    Vogel CL; Smalley RV; Raney M; Krauss S; Carpenter J; Velez-Garcia E; Fishkin E; Raab S; Moore MR; Stagg M
    J Clin Oncol; 1984 Jun; 2(6):643-51. PubMed ID: 6374057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
    Aboud A; Buzdar AU; Yap HY; Hortobagyi GN; Blumenschein GR
    J Surg Oncol; 1984 Jul; 26(3):205-7. PubMed ID: 6610802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
    Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
    Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Bennett JM; Byrne P; Desai A; White C; DeConti R; Vogel C; Krementz E; Muggia F; Doroshow J; Plotkin D
    Invest New Drugs; 1985; 3(2):179-85. PubMed ID: 3894279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
    Büyükünal E; Derman U; Serdengecti S; Berkarda B
    Chemioterapia; 1987 Oct; 6(5):377-9. PubMed ID: 3322590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Taguchi T; Sakai K; Terasawa T; Wada H
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Goodyear M
    J Clin Oncol; 1986 Mar; 4(3):442-4. PubMed ID: 3512787
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of metastatic breast cancer].
    Yahalom J; Biran S; Sulkes A
    Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868
    [No Abstract]   [Full Text] [Related]  

  • 18. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
    Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
    Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Southeastern Cancer Study Group: breast cancer studies 1972-1982.
    Smalley RV; Bartolucci AA; Moore M; Vogel C; Carpenter J; Perez CA; Velez-Garcia E; Marcial V; Lefante J; Wittliff J
    Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1867-74. PubMed ID: 6607245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.